Topical Calcineurin Inhibitors Show No Lymphoma Signal

by | Feb 3, 2026 | Health

A large pharmacovigilance analysis of FDA adverse event reports shows no significant lymphoma safety signal with topical calcineurin inhibitors for atopic dermatitis.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments